ALT — Altimmune, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1326190 ·
Last close
$2.64
Market Cap
$513.41M
52W High
$3.64
52W Low
$2.56
ADV30
2,911,636
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -24,244,000 | -22,563,000 | 335,630,000 | 97,601,000 | 51,643,000 |
| Dec 2025 | 26,000 | — | -28,893,000 | -27,358,000 | 279,929,000 | 43,760,000 | 55,037,000 |
| Sep 2025 | 5,000 | — | -20,859,000 | -19,014,000 | 218,447,000 | 61,236,000 | 32,846,000 |
| Jun 2025 | 5,000 | — | -22,922,000 | -22,146,000 | 190,350,000 | 183,105,000 | 28,983,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-71,637,000
Investing CF
$-131,062,000
Financing CF
$251,196,000
CapEx
$-22,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-672,046,000
Inventory
—
Receivables
$1,665,000
ST Investments
$233,939,000
EBIT TTM
$-88,378,000
Pretax Income TTM
$-91,081,000
Interest Exp TTM
$2,703,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$36,000
EBITDA
$-96,103,000
Free Cash Flow
$-42,502,000
Enterprise Value
$213,829,280
Total Cash
$331,540,000
Total Debt
$35,847,000
Shares Out
194,474,154
Trailing EPS
$-0.92
Book Value
$2.18
ROE
-42.7%
ROA
-24.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 41,000 | -94,489,000 | -88,093,000 | 279,929,000 | 55,037,000 | — | -67,535,000 |
| Dec 2024 | 20,000 | -103,172,000 | -95,059,000 | 139,306,000 | 15,798,000 | — | -79,848,000 |
| Dec 2023 | 426,000 | -83,510,000 | -88,447,000 | 210,640,000 | 16,541,000 | — | -75,810,000 |
| Dec 2022 | -68,000 | -87,740,000 | -84,713,000 | 206,928,000 | 21,635,000 | — | -62,586,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$371,000
NetIncome TTM
$-90,548,000
OpCashFlow TTM
$0
Assets (Latest)
$139,306,000
Forward EPS
$-0.90
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $4.00 · spot: $2.64 · call volume: 213 · put volume: 170
Expected Move to 2027-01-15:
±$1.31
(49.62%) —
implied range
$1.33 –
$3.95
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VREOF | Vireo Growth Inc. | $511.35M | $11.27 | — |
| INDP | Indaptus Therapeutics, Inc. | $509.59M | $4.50 | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $502.08M | $18.21 | — |
| ARVN | ARVINAS, INC. | $494.88M | $7.67 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $534.55M | $0.51 | — |
News headlines (Yahoo Finance, 1h cache)
Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide’s Broader Metabolic Data
2026-06-17 15:16 · Yahoo
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
2026-06-12 15:30 · Yahoo
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near
2026-06-10 13:05 · Yahoo
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other
2026-06-08 17:00 · Yahoo
ALT and the Rise of Dual Agonists Targeting Liver Disease
2026-06-08 16:09 · Yahoo
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
2026-06-08 16:06 · Yahoo
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
2026-06-08 15:53 · Yahoo
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial
2026-06-05 03:08 · Yahoo
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
2026-05-28 15:00 · Yahoo
Altimmune to Participate in Upcoming Investor Conferences
2026-05-27 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.